CathWorks, a Kfar-Saba, Israel-based medical technology company, completed a $30m Series C financing.
The round was led by Deerfield Management.
The company intends to use the funds to accelerate its clinical and commercial activities in the United States.
Led by Jim Corbett, CEO, and and co-founder Guy Lavi, CathWorks is a medical technology company focused on applying its advanced computational science platform to optimize PCI therapy decisions and elevate coronary angiography from visual assessment to an objective FFR-based decision-making tool for physicians. The company’s focus is specifically on bringing its FFRangio system to market to provide objective intraprocedural FFR guidance, practical for every case.
The system received United States Food & Drug Administration 510(k) clearance on December 19, 2018.